Hennion & Walsh Asset Management Inc. Has $1.41 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...
AdvisorNet Financial Inc Buys 4,950 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
news.stocktradersdaily3d
(NTLA) Technical Pivots with Risk Controls
Technical analysis for Intellia Therapeutics Inc. NTLA including support levels resistance levels and stop losses for NTLA ...
Hosted on MSN3d
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Shareholders that lost money on Intellia Therapeutics, Inc. (NTLA) should contact Levi & Korsinsky about Securities Fraud Investigation - NTLA
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Lost Money on Intellia Therapeutics, Inc. (NTLA)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)
Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Intellia Therapeutics, Inc. (NTLA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...